123 related articles for article (PubMed ID: 25618630)
1. Targeted programmed cell death in lung cancer treatment.
Zimmerman MP; Mehr SR
Am J Manag Care; 2014 Mar; 20(5 Spec No.):E3. PubMed ID: 25618630
[No Abstract] [Full Text] [Related]
2. Nivolumab provides favorable results in patients with advanced melanoma.
Dangi-Garimella S
Am J Manag Care; 2014 Mar; 20(5 Spec No.):E11. PubMed ID: 25618626
[No Abstract] [Full Text] [Related]
3. PD-1-targeted immunotherapy: recent clinical findings.
Brahmer JR
Clin Adv Hematol Oncol; 2012 Oct; 10(10):674-5. PubMed ID: 23187774
[No Abstract] [Full Text] [Related]
4. First-Line Immune Therapy-Implications for Pathologists.
Miller RA; Cagle PT; Bernicker EH
Arch Pathol Lab Med; 2016 Aug; 140(8):739-40. PubMed ID: 27472228
[No Abstract] [Full Text] [Related]
5. [Is it possible to treat bronchial carcinoma without chemotherapy?].
Pujol JL
Rev Mal Respir; 2006 Sep; 23(4 Pt 2):10S23-10S26. PubMed ID: 17127957
[No Abstract] [Full Text] [Related]
6. Clinical Trials of PD-1 and PD-L1 inhibitors in NSCLC.
Clin Adv Hematol Oncol; 2014 Jan; 12(1 Suppl 1):14-6. PubMed ID: 24852398
[No Abstract] [Full Text] [Related]
7. Immune Checkpoint Therapy in Non-Small Cell Lung Cancer.
Marrone KA; Brahmer JR
Cancer J; 2016; 22(2):81-91. PubMed ID: 27111902
[TBL] [Abstract][Full Text] [Related]
8. Advances in Immuno-Oncology: Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer-Introduction.
Socinski MA
Semin Oncol; 2015 Oct; 42 Suppl 2():S1-2. PubMed ID: 26477469
[No Abstract] [Full Text] [Related]
9. Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer.
Garon EB
Semin Oncol; 2015 Oct; 42 Suppl 2():S11-8. PubMed ID: 26477470
[TBL] [Abstract][Full Text] [Related]
10. More Benefits for Checkpoint Inhibitors in NSCLC.
Cancer Discov; 2015 Dec; 5(12):OF2. PubMed ID: 26511141
[TBL] [Abstract][Full Text] [Related]
11. American Association of Cancer Research Showcases Immunotherapy Advances.
Brower V
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 26243202
[No Abstract] [Full Text] [Related]
12. [Not Available].
Moro-Sibilot D; Ferrer L; Levra MG; Toffart AC
Bull Cancer; 2016 Jun; 103(6 Suppl 1):S12-5. PubMed ID: 27494968
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy drug improves survival of patients with squamous non-small cell lung cancer.
Printz C
Cancer; 2015 Oct; 121(20):3562-3. PubMed ID: 26431439
[No Abstract] [Full Text] [Related]
14. Checkpoint inhibitor shows promise in smokers.
Cancer Discov; 2013 Dec; 3(12):OF8. PubMed ID: 24327717
[No Abstract] [Full Text] [Related]
15. Nivolumab for advanced non-small cell lung cancer: an evaluation of a phase III study.
Ulmeanu R; Antohe I; Anisie E; Antoniu S
Expert Rev Anticancer Ther; 2016; 16(2):165-7. PubMed ID: 26634873
[TBL] [Abstract][Full Text] [Related]
16. Recent improvement in the survival of patients with advanced nonsmall cell lung cancer enrolled in phase III trials of first-line, systemic chemotherapy.
Bearz A; Serraino D; Fratino L; Berretta M; Tirelli U
Cancer; 2007 Dec; 110(11):2593-4; author reply 2594. PubMed ID: 17960771
[No Abstract] [Full Text] [Related]
17. Targeted therapies in non-small-cell lung cancer: a paradigm in evolution.
Sangha R; Lara PN; Mack P; Gandara DR
Clin Lung Cancer; 2008; 9 Suppl 3():S90-1. PubMed ID: 19419929
[No Abstract] [Full Text] [Related]
18. Epidermal growth factor receptor-directed monoclonal antibodies in nonsmall cell lung cancer: an update.
Pirker R
Curr Opin Oncol; 2015 Mar; 27(2):87-93. PubMed ID: 25636162
[TBL] [Abstract][Full Text] [Related]
19. Controversies around the use of monoclonal antibodies in the treatment of advanced non-small cell lung cancer.
Dediu M; Ion O; Ion R; Gal C; Median D; Gongu M
J BUON; 2009 Sep; 14 Suppl 1():S159-64. PubMed ID: 19785059
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint inhibitors in advanced nonsmall cell lung cancer.
Helissey C; Champiat S; Soria JC
Curr Opin Oncol; 2015 Mar; 27(2):108-17. PubMed ID: 25602683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
